natgillin/translations-raw huggingface dataset:
In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
Pri bolnikih z napredovano HIV infekcijo in z zgodovino opurtunistične infekcije se lahko znaki in simptomi vnetja prejšnje infekcije pojavijo kmalu po uvedbi zdravljenja virusa HIV.
In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your child’s hepatitis.
Pri bolnikih z napredovalo boleznijo jeter ali cirozo se prekinitev zdravljenja ne priporoča, saj pri vašem otroku lahko povzroči poslabšanje hepatitisa.
In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life-threatening.
Pri nekaterih bolnikih z napredovalim obolenjem jeter ali cirozo prenehanje zdravljenja ni priporočeno, saj lahko to povzroči poslabšanje hepatitisa, kar lahko ogrozi življenje.
In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life-threatening.
Pri nekaterih bolnikih z napredovalim obolenjem jeter ali cirozo prenehanje zdravljenja ni priporočeno, saj lahko to povzroči poslabšanje hepatitisa, ki je lahko življenjsko nevarno.
In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function), the co-administration of angiotensin II receptor antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible.
Pri nekaterih bolnikih z zmanjšanim delovanjem ledvic(na primer pri dehidriranih ali starejših z zmanjšanim delovanjem ledvic) lahko sočasno dajanje antagonistov receptorjev angiotenzina II in zdravil, ki zavirajo ciklooksigenazo, povzroči nadaljnje poslabšanje delovanja ledvic, tudi akutno ledvično odpoved, ki je običajno reverzibilna.
In some patients with compromised renal function (eg dehydrated patients or elderly patients with compromised renal function) the co-administration of angiotensin II receptor antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible.
Pri nekaterih bolnikih z zmanjšanim delovanjem ledvic (na primer pri dehidriranih ali starejših z zmanjšanim delovanjem ledvic) lahko sočasno dajanje antagonistov receptorjev angiotenzina II in zdravil, ki zavirajo ciklooksigenazo, povzroči nadaljnje poslabšanje delovanja ledvic, tudi akutno ledvično odpoved, ki je običajno reverzibilna.
In some patients with serious underlying medical conditions who were receiving multiple concomitant medicines along with anidulafungin, clinically significant hepatic abnormalities have occurred.
Klinično pomembne jetrne nenormalnosti so se pojavile nekaterim bolnikom z resnimi osnovnimi boleznimi, ki so sočasno z anidulafunginom dobivali več zdravil.
In some patients, cataplexy may return at a higher frequency on cessation of sodium oxybate therapy, however this may be due to the normal variability of the disease.
Pri nekaterih bolnikih se lahko ob prekinitvi zdravljenja z natrijevim oksibatom spet začne pojavljati katapleksija in to z večjo pogostnostjo, kar pa je lahko tudi posledica običajne spremenljivosti bolezni.
In some patients, erythema and flushing were reported to return with greater severity than was present at baseline.
Poročali so, da se eritem in vročinski oblivi pri nekaterih bolnikih ponovijo v hujši obliki kot pred nanosom (glejte poglavje 4.8).
In some patients, this treatment time may be prolonged.
Pri nekaterih skupinah bolnikov se lahko zdravljenje podaljša.
In some rare cases, especially if your child is taking other medicines that suppress the immune system, reactivation of HBV can be life-threatening.
V redkih primerih, zlasti če vaš otrok uporablja druga zdravila, ki zavirajo imunski sistem, je reaktivacija HBV lahko smrtno nevarna.
In some studies, the double-blind phase was followed by an open- label phase during which all patients received epoetin alfa and a maintenance of effect was observed.
V nekaterih študijah je dvojno slepi fazi sledila odprta faza, v kateri so vsi bolniki prejemali epoetin alfa in kjer so opazili vzdrževalni učinek.
In some the patients, the skin lesions on elbows regressed after CYSTAGON dose reduction.
Pri nekaterih bolnikih so kožne lezije na komolcih po zmanjšanju odmerka zdravila CYSTAGON regredirale.
In some women, uterine fibroids may cause heavy menstrual bleeding (your ‘period’), pelvic pain (discomfort in the belly) and create pressure on other organs.
Pri nekaterih ženskah lahko maternični leiomiomi povzročijo močne menstrualne krvavitve (»mesečno perilo«) in bolečine v medenici (neprijeten občutek v trebuhu) ter pritiskajo na druge organe.
In some, but not all cases, initiation of convulsions appeared to be associated with procedural stress such as handling of the animals.
V nekaterih primerih – ne pa v vseh – je bila sprožitev konvulzij po vsem sodeč povezana s stresom zaradi postopka, npr. rokovanja z živalmi.
In special situations, such as widespread flu, or for patients with a weak immune system, treatment will continue for up to 6 or 12 weeks.
V posebnih primerih, kot je v primeru široko razširjene gripe ali pri bolnikih s šibkim imunskim sistemom, se z zdravljenjem nadaljuje še do 6 ali 12 tednov.
In specifically-designed non-clinical fertility studies in non-human primates, including mating studies, no impairment of male or female fertility was observed following repeated dosing with omalizumab at dose levels up to 75 mg/kg.
V specifično zasnovanih ne- kliničnih študijah plodnosti pri nečloveških primatih, med katere sodijo tudi študije parjenja, po ponavljajočem odmerjanju omalizumaba v odmerkih do 75 mg/kg niso opažali vpliva na plodnost niti pri samcih niti pri samicah.
In specifically-designed non-clinical fertility studies, in non-human primates including mating studies, no impairment of male or female fertility was observed following repeated dosing with omalizumab at dose levels up to 75 mg/kg.
V specifično zasnovanih ne- kliničnih študijah plodnosti pri nečloveških primatih, med katere sodijo tudi študije parjenja, po ponavljajočem odmerjanju omalizumaba v odmerkih do 75 mg/kg niso opažali vpliva na plodnost niti pri samcih niti pri samicah.
In spite of the absence of significant new information reported in this PSUR regarding ONJ, it is suggested that the MAH implements the SmPC, Annex II and PL updates and the patient reminder card with relation to ONJ in order to optimize risk minimisation, as it is considered class information.
Čeprav drugih pomembnih novih informacij o osteonekrozi čeljustnic v tem PSUR ni bilo, je priporočeno, da imetnik dovoljena za promet vnese v povzetek glavnih značilnosti zdravila, prilogo II in navodilo za uporabo spremembe ter pripravi opozorilno kartico za bolnika glede osteonekroze čeljustnic, da zagotovi, da bo tveganje zmanjšano na najvišjo možno mero, saj gre za informacije, ki so skupne celotni skupini teh zdravil.
In SPRING-2, 822 adults were randomized and received at least one dose of either dolutegravir 50 mg once daily or raltegravir (RAL) 400 mg twice daily, both administered with either ABC/3TC or TDF/FTC.
V študiji SPRING-2 je bilo randomiziranih 822 odraslih, ki so prejeli najmanj en odmerek dolutegravirja 50 mg enkrat na dan ali raltegravirja (RAL) 400 mg dvakrat na dan, oboje sočasno z bodisi ABC/3TC ali TDF/FTC.
In SPRING-2, dolutegravir was still non- inferior to raltegravir (viral suppression in 81% vs 76% of patients), and with a median change in CD4 count of 276 vs 264 cells/mm3, respectively.
V študiji SPRING-2 je bil dolutegravir še vedno neinferioren raltegravirju (supresija virusov pri 81 % bolnikih v primerjavi s 76 %), mediana sprememba števila celic CD4 pa je bila 276 v primerjavi z 264 celic/mm3.
In ST segment elevation myocardial infarction, fewer patients on Clopidogrel BMS had events than patients on placebo (262 against 377 in the CLARITY study, and 2,121 against 2,310 in the COMMIT study).
Pri miokardnem infarktu z elevacijo spojnice ST je bilo število bolnikov, pri katerih so se pojavili dogodki, manjše med bolniki, ki so jemali zdravilo Clopidogrel BMS, kot med bolniki, ki so prejemali placebo (262 v primerjavi s 377 v študiji CLARITY ter 2 121 v primerjavi z
In Still’s disease (AOSD or SJIA), you should not inject Ilaris earlier than 4 weeks after the last dose.
Če imate Stillovo bolezen (AOSD ali SJIA), zdravila Ilaris ne smete injicirati prej kot 4 tedne po zadnjem odmerku.
In Still’s disease, patients with a body weight of 7.5 kg or above are given 4 mg per kilogram body weight (up to a maximum dose of 300 mg) as an injection under the skin every four weeks.
Pri Stillovi bolezni dobijo bolniki s telesno maso 7,5 kg ali več 4 mg zdravila na kilogram telesne mase (do največjega odmerka 300 mg) vsake štiri tedne v obliki injekcije pod kožo.
In studies 1 and 2 in patients with the G551D mutation in one allele of the CFTR gene, ivacaftor led to rapid (15 days), substantial (the mean change in sweat chloride from baseline through week 24 was -48 mmol/L [95% CI -51, -45] and -54 mmol/L [95% CI -62, -47], respectively) and sustained (through 48 weeks) reductions in sweat chloride concentration.
V študijah 1 in 2 pri bolnikih z mutacijo G551D v enem alelu gena CFTR je ivakaftor povzročil hitro (15 dni), znatno (povprečna sprememba klorida v znoju od izhodišča do 24. tedna je bila -48 mmol/l [95 % CI -51, -45] oziroma -54 mmol/l [95 % CI -62, -47]) in trajna (48 tednov) znižanja koncentracije kloridov v znoju.
In studies 312-0116/0117 and 312-0119, rash (reported as dermatitis exfoliative, rash, rash erythematous, rash generalised, rash macular, rash maculo-papular, rash papular, rash pruritic, and skin disorder) occurred in 28.3% of subjects who received idelalisib + an anti-CD20 monoclonal antibody (rituximab or ofatumumab) and 7.7% who received an anti-CD20 monoclonal antibody only (rituximab or ofatumumab).
V študijah 312-0116/0117 in 312-0119 se je izpuščaj (o njem so poročali kot o eksfoliativnem dermatitisu, izpuščaju, eritematoznem izpuščaju, generaliziranem izpuščaju, makularnem izpuščaju, makulopapularnem izpuščaju, papularnem izpuščaju, pruritičnem izpuščaju in kožni motnji) pojavil pri 28,3 % oseb, ki so prejemale idelalizib + monoklonsko protitelo proti CD20 (rituksimab ali ofatumumab), in pri 7,7 % oseb, ki so prejemale samo monoklonsko protitelo proti CD20 (rituksimab ali ofatumumab).
In studies conducted in healthy subjects, neither the pharmacokinetics of saxagliptin and its major metabolite, were meaningfully altered by metformin, glibenclamide, pioglitazone, digoxin, simvastatin, omeprazole, antacids or famotidine.
Metformin, glibenklamid, pioglitazon, digoksin, simvastatin, omeprazol, antacidi in famotidin v študijah pri zdravih prostovoljcih niso bistveno spremenili farmakokinetike saksagliptina in njegovega glavnega presnovka.
In studies conducted in healthy subjects, neither the pharmacokinetics of saxagliptin and its major metabolite, were meaningfully altered by metformin, glibenclamide, pioglitazone, digoxin, simvastatin, omeprazole, antacids or famotidine.
Metformin, glibenklamid, pioglitazon, digoksin, simvastatin, omeprazol, antacidi in famotidin v študijah zdravih prostovoljcev niso bistveno spremenili farmakokinetike saksagliptina in njegovega glavnega presnovka.
In studies conducted in healthy subjects, neither the pharmacokinetics of saxagliptin nor its major metabolite were meaningfully altered by metformin, glibenclamide, pioglitazone, digoxin, simvastatin, omeprazole, antacids or famotidine.
Metformin, glibenklamid, pioglitazon, digoksin, simvastatin, omeprazol, antacidi in famotidin v študijah pri zdravih osebah niso bistveno spremenili farmakokinetike saksagliptina in njegovega glavnega presnovka.
In studies demonstrating superiority of XGEVA to zoledronic acid, patients were offered open label XGEVA in a pre-specified 2-year extension treatment phase.
V študijah, ki so pokazale superiornost zdravila XGEVA pred zoledronsko kislino, so bolnikom ponudili odprto uporabo zdravila XGEVA v vnaprej opredeljeni fazi 2-letnega podaljšanega zdravljenja.
In studies DPM-CF-301 and 302 relative % predicted FEV1 compared to control in children (6-11 years) was improved by 0.44% (95% CI -5.90, 6.77, N=43) and 6.1% (95% CI -1.28, 13.54, N=59) over 26 weeks (p=0.892 and 0.104) respectively.
Pri otrocih (6–11 let) se je v 26 tednih relativna odstotkovna vrednost napovedanega FEV1 v primerjavi s kontrolno skupino v študiji DPM-CF-301 izboljšala za 0,44 % (95-odstotni IZ: -5,90; 6,77, n=43, p=0,892), v študiji 302 pa za 6,1 % (95-odstotni IZ: -1,28; 13,54, n=59, p=0,104).
In Studies ESTEEM 1 and ESTEEM 2, significant improvements (reductions) in nail psoriasis, as measured by the mean percent change in Nail Psoriasis Severity Index (NAPSI) from baseline, were observed in patients receiving apremilast compared to placebo-treated patients at Week 16 (p< 0.0001 and p=0.0052, respectively).
V študijah ESTEEM 1 in ESTEEM 2 so opazili pri bolnikih, ki so 16 tednov prejemali apremilast, v primerjavi z bolniki, ki so prejemali placebo, pomembno izboljšanje (zmanjšanje) psoriaze nohtov, izmerjene s povprečno odstotno spremembo indeksa izraženosti psoriaze nohtov (Nail Psoriasis Severity Index (NAPSI)) od izhodišča (p< 0,0001 oziroma p=0,0052).
In Studies ESTEEM 1 and ESTEEM 2, significant improvements in quality of life as measured by the Dermatology Life Quality Index (DLQI) and the SF-36v2MCS were demonstrated in patients receiving apremilast compared with placebo-treated patients (Table 4).
V študijah ESTEEM 1 in ESTEEM 2 so dokazali signifikantno izboljšanje kvalitete življenja, izmerjene z dermatološkim indeksom kvalitete življenja (Dermatology Life Quality Index (DLQI)) in s SF-36v2MCS pri bolnikih, ki so prejemali apremilast, v primerjavi z bolniki, ki so prejemali placebo (preglednica 4).
In Studies ESTEEM 1 and ESTEEM 2, significant improvements in scalp psoriasis of at least moderate severity (≥3), measured by the proportion of patients achieving Scalp Psoriasis Physician’s Global Assessment (ScPGA) of clear (0) or minimal (1) at Week 16, were observed in patients receiving apremilast compared to placebo-treated patients (p< 0.0001 for both studies).
V študijah ESTEEM 1 in ESTEEM 2 so pri bolnikih, ki so prejemali apremilast, v primerjavi z bolniki, ki so prejemali placebo, opazili pomembno izboljšanje psoriaze lasišča vsaj zmerne izraženosti (≥3), izmerjene z deležem bolnikov, ki so po 16 tednih dosegli zdravnikovo globalno oceno psoriaze lasišča (ScPGA) čisto (0) ali minimalno (1) (p< 0,0001 v obeh študijah).
In studies evaluating MabThera in combination with chemotherapy, the incidence of grade 3 and 4 cardiac arrhythmias, predominantly supraventricular arrhythmias such as tachycardia and atrial flutter/fibrillation, was higher in the R-CHOP group (14 patients, 6.9%) as compared to the CHOP group (3 patients, 1.5%).
V študijah z zdravilom MabThera v kombinaciji s kemoterapijo je bila incidenca motenj srčnega ritma 3. ali 4. stopnje, predvsem supraventrikularnih aritmij, kot sta tahikardija in atrijska fibrilacija/undulacija, višja v skupini R-CHOP (14 bolnikov, 6,9 %) kot pa v skupini CHOP (3 bolniki, 1,5 %).
In studies GS-US-292-0104 and GS-US-292-0111, E/C/F/TAF met the non-inferiority criteria in achieving HIV-1 RNA < 50 copies/mL when compared to E/C/F/TDF.
V študijah GS-US-292-0104 in GS-US-292-0111 je zdravilo E/C/F/TAF izpolnilo kriterije enakovrednosti pri doseganju HIV-1 RNA < 50 kopij/ml v primerjavi z E/C/F/TDF.
In studies GS-US-292-0104 and GS-US-292-0111, patients were randomised in a 1:1 ratio to receive either emtricitabine 200 mg and tenofovir alafenamide 10 mg (n = 866) once daily or emtricitabine 200 mg + tenofovir disoproxil (as fumarate) 245 mg (n = 867) once daily, both given with elvitegravir 150 mg + cobicistat 150 mg as a fixed-dose combination tablet.
V študijah GS-US-292-0104 in GS-US-292-0111 so bolnike randomizirali v razmerju 1:1 za prejemanje emtricitabina 200 mg in alafenamidtenofovirata 10 mg (n = 866) enkrat dnevno ali emtricitabina 200 mg + dizoproksiltenofovirata (v obliki fumarata) 245 mg (n = 867) enkrat dnevno, oboje uporabljeno z elvitegravirjem 150 mg + kobicistatom 150 mg v obliki tablete s fiksno kombinacijo odmerkov.
In studies GS-US-292-0104 and GS-US-292-0111, patients were randomised in a 1:1 ratio to receive either Genvoya (n = 866) once daily or elvitegravir 150 mg/cobicistat 150 mg/emtricitabine
V študijah GS-US-292-0104 in GS-US-292-0111 so bolnike randomizirali v razmerju 1:1 za prejemanje zdravila Genvoya (n = 866) enkrat dnevno ali elvitegravir 150 mg/kobicistat
In studies GS-US-292-0104 and GS-US-292-0111, the rate of virologic success was similar across patient subgroups (age, gender, race, baseline HIV-1 RNA, or baseline CD4+ cell count).
V študijah GS-US-292-0104 in GS-US-292-0111, je bila stopnja virološke uspešnosti podobna pri vseh podskupinah bolnikov (starost, spol, rasa, začetna vrednost HIV-1 RNA ali začetno število celic CD4+).
In Studies I-IV, Trudexa-treated patients achieved statistically significant ACR 20 and 50 responses compared to placebo as early as one to two weeks after initiation of treatment.
V študijah I–IV so bolniki, zdravljeni s Trudexo, v primerjavi s prejemniki placeba doživeli statistično značilen odziv 20 in 50 po ACR že en do dva tedna po začetku zdravljenja.
In Studies I-IV, Trudexa-treated patients achieved statistically significant ACR 20 and 50 responses compared to placebo as early as one to two weeks after initiation of treatment.
V študijah I–IV so s Trudexo zdravljeni bolniki v primerjavi s prejemniki placeba dosegli statistično značilen odziv 20 in 50 po ACR že en do dva tedna po začetku zdravljenja.
In Studies II, III and V, tocilizumab was administered intravenously every four weeks in combination with MTX vs. placebo and MTX.
V študijah II, III in V so tocilizumab dajali intravensko na štiri tedne v kombinaciji z metotreksatom; primerjava je bila kombinacija placeba in metotreksata.
In studies implementing routine antibacterial soaking of the treatment area before and after NexoBrid application (see section 4.2) pyrexia or hyperthermia was reported in 19.1% of patients treated with NexoBrid and in 15.8% of the control patients treated according standard of care.
V študijah, kjer so rutinsko uporabljali protibakterijsko namakanje zdravljenega predela pred nanosom zdravila NexoBrid in po njem (glejte poglavje 4.2) pri 19,1 bolnikih, zdravljenih z zdravilom NexoBrid in pri 15,8 % bolnikov iz kontrolne skupine, zdravljenih s standardno nego, poročali o pireksiji ali hipertermiji.
In studies in adults and children with plaque psoriasis, a higher proportion of patients receiving Humira had improvements in symptoms compared with patients receiving methotrexate.
Študije pri odraslih in otrocih s psoriazo v plakih so pokazale, da je do izboljšanja prišlo pri več bolnikih, ki so jemali zdravilo Humira, kot pri tistih, ki so jemali metotreksat.
In studies in children, Invanz was compared with ceftriaxone (community-acquired pneumonia, 389 children) and ticarcillin/clavulanate (intra- abdominal infections, 105 children).
V študijah pri otrocih so zdravilo Invanz primerjali s ceftriaksonom (zunajbolnišnična pljučnica, 389 otrok) in tikarcilinom/klavulanatom (okužbe v trebušni votlini, 105 otrok).
In studies in healthy subjects and epileptic adult patients, the apparent half-life of eslicarbazepine was 10-20 h and 13-20 h, respectively.
V študijah pri zdravih osebah je bil razpolovni čas eslikarbazepina 10–20 h, pri odraslih bolnikih z epilepsijo pa 13–20 h.
In studies in healthy subjects and epileptic adult patients, the apparent half-life of eslicarbazepine was 10-20 hours and 13-20 hours, respectively.
V študijah pri zdravih osebah je bil razpolovni čas eslikarbazepina 10–20 h, pri odraslih bolnikih z epilepsijo pa 13–20 h.
In studies in patients with compensated liver disease, histological improvement was defined as a ≥ 2- point decrease in Knodell necro-inflammatory score from baseline with no worsening of the Knodell fibrosis score.
V študijah pri bolnikih s kompenzirano boleznijo jeter, je bilo izboljšanje histološke slike definirano kot zmanjšanje stopnje vnetja in nekroze po Knodell-u ("Knodell necro-inflammatory score") za 2 ali več točk od izhodiščne vrednosti in brez poslabšanja stopnje fibroze po Knodell-u ("Knodell Fibrosis Score").
In studies in treatment- naïve patients, increases from baseline were observed in both the tenofovir alafenamide fumarate and tenofovir disoproxil fumarate containing treatment groups for the fasting lipid parameters total cholesterol, direct low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)-cholesterol, and triglycerides at Week 96.
V študijah pri predhodno nezdravljenih bolnikih so v 96. tednu opazili povečanje od začetne vrednosti v obeh skupinah zdravljenja, v skupini z alafenamidtenofoviratom in skupini z dizoproksiltenofovirat fumaratom, pri parametrih maščob na tešče za skupni holesterol, direktni holesterol lipoproteinov nizke gostote (low-density lipoprotein, LDL) ali LDL holesterol, holesterol lipoproteinov visoke gostote (high-density lipoprotein, HDL) ali HDL holesterol in trigliceride.
In studies in treatment-naïve adult patients, E/C/F/TAF was associated with lower impact on renal safety parameters (as measured by eGFRCG, urine protein to creatinine ratio and urine albumin to creatinine ratio) compared to E/C/F/TDF after 96 weeks of treatment (see also section 4.4).
V študijah predhodno nezdravljenih odraslih bolnikov je bilo po 96 tednih zdravljenja zdravilo E/C/F/TAF povezano z manjšim vplivom na parametre varnosti za ledvice (izmerjeno z eGFRCG, razmerjem med beljakovinami in kreatininom in razmerjem med albuminom v urinu in kreatininom) v primerjavi z E/C/F/TDF (glejte tudi poglavje 4.4).
In studies in treatment-naïve adult patients, E/C/F/TAF was associated with smaller reductions in bone mineral density (BMD; as measured by hip and lumbar spine DXA analysis) compared to E/C/F/TDF after 96 weeks of treatment.
V študijah pri predhodno nezdravljenih bolnikih je bilo E/C/F/TAF po 96 tednih zdravljenja povezano z manjšim zmanjšanjem mineralne gostote kosti (MGK), ki se je merila z analizo DXA kolka in ledvene hrbtenice) kot E/C/F/TDF.
In studies in treatment-naïve patients, emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat (through 96 weeks) or darunavir and cobicistat (through 48 weeks) as a fixed-dose combination tablet was associated with smaller reductions in bone mineral density (BMD; as measured by hip and lumbar spine dual energy X ray absorptiometry [DXA] analysis) compared to E/C/F/TDF or darunavir, cobicistat, emtricitabine and tenofovir disoproxil fumarate.
V študijah pri predhodno nezdravljenih bolnikih je bil emtricitabin + alafenamidtenofovirat v kombinaciji z elvitegravirjem + kobicistatomom (do vključno 96. tedna) ali darunavirjem + kobicistatom (do vključno 48. tedna) v obliki tablete s fiksno kombinacijo odmerkov povezan z manjšim zmanjšanjem mineralne gostote kosti (MGK; ki se je merila z dvoenergijsko rentgensko absorpciometrijo analizo [DXA] kolka in ledvene hrbtenice) kot E/C/F/TDF ali darunavir, kobicistat, emtricitabin in dizoproksiltenofovirat fumarat.